眼科領域的聯盟和許可協議：2019-2024

Ophthalmics Collaboration and Licensing Deals 2019-2024

出版日期: 2024年10月01日 | 出版商:

Current Partnering | 英文 200+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告調查了眼科領域的聯盟和許可協議，分析了2019年以來的合約趨勢、眼科領域的聯盟和許可協議、基準分析-交易的市場價值、財務狀況、主要交易金額以及最A活躍交易者摘要。

簡介
眼科治療目標的交易
交易目錄
交易目錄 - 按公司劃分的眼科交易（2019-2024 年）
交易目錄 - 按技術類型劃分的眼科交易（2019-2024 年）
交易類型的定義
關於生物製藥研究股份有限公司
目前的合作關係
當前合約
目前合作夥伴的最新報告標題

簡介目錄

Product Code: CP2219

Ophthalmics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the ophthalmics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 327 ophthalmics deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in ophthalmics dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the ophthalmics field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in ophthalmics dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of ophthalmics deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of ophthalmics deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in ophthalmics deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse ophthalmics collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Ophthalmics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of ophthalmics trends and structure of deals entered into by leading biopharma companies worldwide.

Ophthalmics Collaboration and Licensing Deals includes:

Trends in ophthalmics dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of ophthalmics deal records covering pharmaceutical and biotechnology
The leading ophthalmics deals by value
Most active ophthalmics licensing dealmakers

In Ophthalmics Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Ophthalmics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?